|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, the identification of CD133(+) cells could thus be a potentially powerful tool to investigate the tumorigenic process in the hepatoma system and to also develop effective therapies targeted against hepatocellular carcinoma.
|
17097610 |
2006 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
The implication that CD133 might be one of the markers for HCC cancer stem-like cells needed further investigation.
|
17205516 |
2007 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HPC markers, K7, K19, prominin-1, receptor for stem cell factor c-kit, octamer-4 transcription factor, and leukemia inhibitory factor were upregulated (P < 0.05), while albumin was downregulated in CLC (P = 0.007) toward K19-negative HCCs.
|
18393293 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrated that forced re-expression of HNF4alpha induced the differentiation of hepatoma cells into hepatocytes, dramatically decreased "stemness" gene expression and the percentage of CD133(+) and CD90(+) cells, which are considered as cancer stem cells in HCC.
|
18925631 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Of 154 patients, 24 (15.6%) had CD133 expression in HCC.
|
19744348 |
2009 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD133 expression was observed in three HCC (HuH7, PLC5 and HepG2) and two cholangiocarcinoma cell lines (HuCCT1 and CCKS1).
|
19842219 |
2009 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TGFbeta1 is capable of up-regulating CD133 expression specifically within the Huh7 HCC cell line in a time- and dose-dependent manner.
|
20196115 |
2010 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We derived two different HCC cell lines by (1) transfection of CD133 siRNA in PLC/PRF/5 cells in (CD133si-PLC/PRF/5), and (2) by a magnetic cell sorting method that allowed to divide Huh7 cells into two CD133 positive (+) and negative (-) groups.
|
20395004 |
2010 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The human HCCs were divided into the CD133-high group (top 40%) and the CD133-low group (bottom 40%) according to the level of CD133 mRNA.
|
20969862 |
2011 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Subsequent differential microRNA expression profiling of CD133(+) and CD133⁻ cells from human HCC clinical specimens and cell lines identified an overexpression of miR-130b in CD133(+) TICs.
|
21112564 |
2010 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conversion of AKT/CAT tumor cells to frank HCC during passage was associated with induction of the human HCC marker α-fetoprotein and the stem cell marker CD133.
|
21324921 |
2011 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HCC with demethylation of Line-1 had elevated CD133 expression in tumor rather than matched nontumor tissues (mean -∆(∆Ct) = 1.101), but HCC with hypermethylation of Line-1 was considered to be lower with CD133 expression in tumor (mean -∆(∆Ct) = -0.409).
|
21331808 |
2011 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, overexpression of the DLK1-DIO3 miRNA cluster was positively correlated with HCC stem cell markers (CD133, CD90, EpCAM, Nestin) and associated with a high level of serum α-fetoprotein, a conventional biomarker for liver cancer, and poor survival rate in HCC patients.
|
21737452 |
2011 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicate that hexokinase II is vitally meaningful for CD133+ hepatoma BEL-7402 cells.
|
21909686 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we examined the expression of cancer stem cell (CSC) marker CD133, the activation of insulin-like growth factor 1 receptor (IGF-1R) signaling, and the nuclear translocation of IGF-1R in HCC Mahlavu cells under the treatment of gefitinib, a cancer drug that inhibits epidermal growth factor receptor (EGFR) pathway.
|
21959795 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IL-8 was found to be overexpressed at both the genomic and proteomic levels in CD133(+) cells isolated from HCC cell lines or clinical samples.
|
21994122 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.
|
22079466 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we determine VM capacity and expression of stemness genes (Oct4, Sox2, Nanog and CD133) in well- and poorly-differentiated HCC cell lines.
|
22580004 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, we found that low-dose exogenous BMP4 upregulated CD133 protein expression in vitro, and endogenous BMP4 was preferentially expressed in CD133+ HCC CSCs, suggesting that low doses of BMP4 may facilitate CSC maintenance.
|
22773665 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Understanding the characteristics and function of CD133(+) liver CSCs has also shed light on HCC management and treatment, including the implications for prognosis, prediction and treatment resistance.
|
22999864 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, the stem-targeted therapy via CD133 could provide a novel strategy for the treatment of HCC.
|
23233126 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore the self-renewal ability and chemotherapy resistance in liver CSCs, we enriched CD90(+)CD133(+) hepatocellular carcinoma (HCC) CSCs using sphere formation, which was accomplished by cultivating HCC CSCs from established HCC cell lines (HepG2 line and Hep3B line).
|
23438193 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Telomeres were significantly longer in HCCs expressing "stemness"-related proteins (K19: p < 0.001, EpCAM: p = 0.002, CD133: p = 0.002).
|
23685049 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to isolate and characterize a small population of CD133+ cells that existed in the HCC cell line SMMC-7721 by MACS and investigated the possible roles of 8-bromo-7-methoxychrysin (BrMC), a synthetic analogue of chrysin, in inhibiting the properties of CD133+ sphere-forming cells (SFCs) derived from the HCC cell line SMMC-7721, namely liver cancer stem cells (LCSCs).
|
23970349 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ABCG2 was preferentially expressed in highly chemoresistant hepatocellular carcinoma cancer stem cells (CSC) enriched with CD133.
|
24130050 |
2013 |